A Holistic Phase Appropriate Strategy for HCP-Limits and HCP Characterization
Posted on April 30, 2018
Dr. Markus Haindl, Director Development Analytics
Roche Diagnostics GmbH, Germany
Introduction During manufacturing of biopharmaceuticals prokaryotic and eukaryotic protein expression host systems like Escherichia coli (E. coli) and Chinese Hamster Ovary (CHO) cells generate a heterogeneous mixture of the desired therapeutic protein and a variety of endogenous host cell proteins ...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
biopharmaceuticals prokaryotic, CHO, endogenous, eukaryotic protein expression, HCP Characterization, HCP-Limits, HCPs, Holistic, host-cell proteins, immunological, Phase Appropriate, physicochemical, therapeutic protein
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
